Altered mucosal and plasma polyunsaturated fatty acids, oxylipins, and endocannabinoids profiles in Crohn's disease

Prostaglandins Other Lipid Mediat. 2023 Oct:168:106741. doi: 10.1016/j.prostaglandins.2023.106741. Epub 2023 May 4.

Abstract

Selected mucosal and plasma polyunsaturated fatty acids (PUFAs) and related oxylipins and endocannabinoids were determined in 28 Crohn's disease (CD) patients and 39 controls. Fasting blood and colonic biopsies were collected in all participants, during a disease flare for the patients. Thirty-two lipid mediators including PUFAs, oxylipins, and endocannabinoids were assessed by LC-MS/MS. The pattern of lipid mediators in CD patients is characterized by an increase in arachidonic acid-derived oxylipins and endocannabinoids and a decrease in n-3 PUFAs and related endocannabinoids. A model combining increased 6-epi-lipoxin A4 and 2-arachidonyl glycerol with decreased docoasapentaenoic acid in plasma fairly discriminates patients from controls and may represent a lipidomic signature for CD flare. The study findings suggest that lipid mediators are involved in CD pathophysiology and may serve as biomarkers for disease flare. Further research is required to confirm the role of these bioactive lipids and test their therapeutic potential in CD.

Keywords: Crohn’s disease; Endocannabinoids; Lipidomic; Oxylipins; Polyunsaturated fatty acids.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chromatography, Liquid
  • Crohn Disease*
  • Endocannabinoids
  • Fatty Acids
  • Fatty Acids, Omega-3*
  • Fatty Acids, Unsaturated
  • Humans
  • Oxylipins
  • Symptom Flare Up
  • Tandem Mass Spectrometry

Substances

  • Oxylipins
  • Endocannabinoids
  • Fatty Acids, Unsaturated
  • Fatty Acids, Omega-3
  • Fatty Acids